Antibody-targeted drugs and drug resistance—challenges and solutions
LR Shefet-Carasso, I Benhar - Drug Resistance Updates, 2015 - Elsevier
Antibody-based therapy of various human malignancies has shown efficacy in the past 30
years and is now one of the most successful and leading strategies for targeted treatment of
patients harboring hematological malignancies and solid tumors. Antibody–drug conjugates
(ADCs) aim to take advantage of the affinity and specificity of monoclonal antibodies (mAbs)
to selectively deliver potent cytotoxic drugs to antigen-expressing tumor cells. Key
parameters for ADC include choosing the optimal components of the ADC (the antibody, the …
years and is now one of the most successful and leading strategies for targeted treatment of
patients harboring hematological malignancies and solid tumors. Antibody–drug conjugates
(ADCs) aim to take advantage of the affinity and specificity of monoclonal antibodies (mAbs)
to selectively deliver potent cytotoxic drugs to antigen-expressing tumor cells. Key
parameters for ADC include choosing the optimal components of the ADC (the antibody, the …